Skip to main content
Caplight Logo









AffaMed Therapeutics

AffaMed Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://affamed.com/

Last Round

Series B

Mar 30, 2021

Total Funding Raised

$250M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AffaMed Therapeutics is a biopharmaceutical company that develops and commercializes transformative pharmaceutical products for ophthalmic, neurological, and psychiatric disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Keywords

ophthalmologybiopharmaceuticalclinical stage pharmabiotechdrug developmentin-licensingmedical devicesmedtechChina healthcare marketophthalmic therapiesintraocular lensesIOLsbiologicsneurological disordersdigital therapeuticsDTxpsychiatric disordersAI therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AffaMed Therapeutics Comparables

Compare AffaMed Therapeutics with similar companies based on industry and business-model similarity.

AffaMed Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Arctic Vision
88%
Allgenesis Biotherapeutics Inc.
80%
Ocumension Therapeutics
78%

AffaMed Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 30, 2021
Series AFeb 1, 2019

AffaMed Therapeutics Investors

Notable investors and investment history

AffaMed Therapeutics investors
InvestorRounds
Lake Bleu CapitalSeries B
CBC GroupSeries B, Series A
Superstring Capital ManagementSeries B
Fountainhead PartnersSeries B
Partners InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Open roles increased to 8, 4x the trailing average.

  • Jul 20, 2026

    Open roles increased from 0 to 8, representing 25% of headcount.

AffaMed Therapeutics Filings

Explore SEC and related filing metadata, where available.

AffaMed Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AffaMed Therapeutics's valuation, stock price, and market status.

Is AffaMed Therapeutics a public or private company?

AffaMed Therapeutics is a private company.

What is the current stock price of AffaMed Therapeutics?

AffaMed Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AffaMed Therapeutics worth (valuation)?

Valuation information for AffaMed Therapeutics is not publicly available.

Can I buy AffaMed Therapeutics stock?

AffaMed Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AffaMed Therapeutics's last funding round?

Funding round information for AffaMed Therapeutics is not publicly available.

Who are the main investors in AffaMed Therapeutics?

Investor information for AffaMed Therapeutics is not publicly disclosed.

Will AffaMed Therapeutics IPO soon?

No public IPO plans have been announced for AffaMed Therapeutics.

How can I track AffaMed Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AffaMed Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range30
Year Founded2019
Last FundingMar 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?